<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74033">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116543</url>
  </required_header>
  <id_info>
    <org_study_id>0110</org_study_id>
    <nct_id>NCT02116543</nct_id>
  </id_info>
  <brief_title>TD-6450 MAD Study in HCV Infected Subjects</brief_title>
  <official_title>A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof of concept study is designed to evaluate the safety, tolerability,
      pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1,
      GT-2 or GT-3 chronic HCV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number, type, severity, and association of treatment emergent adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral Activity</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in HCV RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>t1/2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>TD-6450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-6450 capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-6450</intervention_name>
    <arm_group_label>TD-6450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is HCV antibody positive

          -  Subject is treatment naïve, with no history of exposure (single or multiple dose) to
             interferon, ribavirin or direct acting antivirals.

          -  Subject has had a liver biopsy within 3 years or Fibroscan evaluation within 6 months
             prior to Screening that clearly excludes cirrhosis.   If not available prior to
             Screening, the absence of cirrhosis must be confirmed prior to subject enrollment
             using either Fibroscan or Fibrosure®.

          -  Subject is negative for hepatitis A (HAV), hepatitis B (HBV), and human
             immunodeficiency virus (HIV).

        Exclusion Criteria:

          -  Subject has prior histological evidence of cirrhosis or current clinical evidence of
             cirrhosis in the opinion of the investigator.

          -  Subject has a history or evidence of non-hepatitis C chronic liver disease.

          -  Subject has an estimated creatinine clearance of &lt;80 ml/min if 18-60 years of age,
             inclusive; or &lt;70 ml/min if &gt;60 years of age, calculated using the Cockcroft-Gault
             equation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger Kohler</last_name>
    <phone>650-808-6400</phone>
    <email>Rkohler@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz, M.D.</last_name>
      <phone>210-572-4997</phone>
    </contact>
    <investigator>
      <last_name>Eric Lawitz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
